about
Monotherapy for partial epilepsy: focus on levetiracetamAssessment into the usage of levetiracetam in a canine epilepsy clinicPsychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapyDoes pyridoxine control behavioral symptoms in adult patients treated with levetiracetam? Case series from UAEInduction of endogenous pathways by antiepileptics and clinical implications.Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures.Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy.Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.Levetiracetam Differentially Alters CD95 Expression of Neuronal Cells and the Mitochondrial Membrane Potential of Immune and Neuronal Cells in vitro.Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies.Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects.Much ado about something or nothing: behavioral problems with levetiracetam use in epilepsy patientsSafety of Supratherapeutic Doses of Newer Antiepileptic Drugs in Children: What Have We Really Learned?"Mu rhythm status" and clinical correlates.Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis.Assessment of a dose-response relationship of levetiracetam.A Psychiatric Side Effect of Levetiracetam Can Mimic a Relapse of Anti-Leucine-Rich Glioma Inactivated 1 Encephalitis.
P2860
Q24644605-B72D655D-E718-4882-B11B-644AE3CD5E42Q35084185-208B84DD-E235-4238-A967-9AF91167C738Q35539645-165A7961-A01E-4664-93EF-6A5773CCB0DAQ36106423-D6B98DE5-4C29-48F2-9F50-3A7D8BF6EAC0Q36263605-6F5FAFB8-C1BE-42A5-8565-93488FE39F99Q36423522-ED2F47A7-7C99-4629-823E-14C6AC885FA6Q36703584-CCD43365-1B19-42DD-B613-5AFA9DC4034BQ36802676-D98E2327-A71F-4C06-A038-8C33307B1918Q39237618-9C226B96-D1EF-45D8-81D7-45962ED02056Q40267179-1C58E941-CC0E-413A-9FC9-FF24735DA60BQ41125106-364A340C-812F-4B79-A58A-C5B43F1AC0A8Q42283009-52A92D14-B77F-4557-A8DA-FBD71DB5A168Q42347204-96030078-5573-4518-B67B-5C6DB0BE472BQ44911791-C3EBF140-A999-48FB-A597-AEF8DC50C2B8Q47601973-AE8996CF-7A11-44F5-871D-39B046D55C6EQ52930964-12F91CAF-BFA5-420A-A3E1-C69A9864D7A5Q55445240-25241691-9456-4872-8AF7-8C9F5B8E0B14
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety profile of levetiracetam.
@ast
Safety profile of levetiracetam.
@en
Safety profile of levetiracetam.
@nl
type
label
Safety profile of levetiracetam.
@ast
Safety profile of levetiracetam.
@en
Safety profile of levetiracetam.
@nl
prefLabel
Safety profile of levetiracetam.
@ast
Safety profile of levetiracetam.
@en
Safety profile of levetiracetam.
@nl
P2860
P1433
P1476
Safety profile of levetiracetam.
@en
P2093
P2860
P356
10.1046/J.1528-1157.2001.0420S4036.X
P478
42 Suppl 4
P577
2001-01-01T00:00:00Z